Anti-ZNF536 monoclonal antibody

Pre-made anti-ZNF536 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to ZNF536/ZNF536 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP2836-Ab-1/ GM-Tg-hg-IP2836-Ab-2Anti-Human ZNF536 monoclonal antibodyHuman
GM-Tg-rg-IP2836-Ab-1/ GM-Tg-rg-IP2836-Ab-2Anti-Rat ZNF536 monoclonal antibodyRat
GM-Tg-mg-IP2836-Ab-1/ GM-Tg-mg-IP2836-Ab-2Anti-Mouse ZNF536 monoclonal antibodyMouse
GM-Tg-cynog-IP2836-Ab-1/ GM-Tg-cynog-IP2836-Ab-2Anti-Cynomolgus/ Rhesus macaque ZNF536 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP2836-Ab-1/ GM-Tg-felg-IP2836-Ab-2Anti-Feline ZNF536 monoclonal antibodyFeline
GM-Tg-cang-IP2836-Ab-1/ GM-Tg-cang-IP2836-Ab-2Anti-Canine ZNF536 monoclonal antibodyCanine
GM-Tg-bovg-IP2836-Ab-1/ GM-Tg-bovg-IP2836-Ab-2Anti-Bovine ZNF536 monoclonal antibodyBovine
GM-Tg-equg-IP2836-Ab-1/ GM-Tg-equg-IP2836-Ab-2Anti-Equine ZNF536 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP2836-Ab-1/ GM-Tg-hg-IP2836-Ab-2; GM-Tg-rg-IP2836-Ab-1/ GM-Tg-rg-IP2836-Ab-2;
GM-Tg-mg-IP2836-Ab-1/ GM-Tg-mg-IP2836-Ab-2; GM-Tg-cynog-IP2836-Ab-1/ GM-Tg-cynog-IP2836-Ab-2;
GM-Tg-felg-IP2836-Ab-1/ GM-Tg-felg-IP2836-Ab-2; GM-Tg-cang-IP2836-Ab-1/ GM-Tg-cang-IP2836-Ab-2;
GM-Tg-bovg-IP2836-Ab-1/ GM-Tg-bovg-IP2836-Ab-2; GM-Tg-equg-IP2836-Ab-1/ GM-Tg-equg-IP2836-Ab-2
Products NameAnti-ZNF536 monoclonal antibody
Formatmab
Target NameZNF536
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-ZNF536 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP2836-Ag-1Recombinant multi-species ZN536/ ZNF536 protein


    Target information

    Target IDGM-IP2836
    Target NameZNF536
    Gene ID9745,243937,292820,713142,119863924,101093314,520269,100054074
    Gene Symbol and Synonyms9630010P11Rik,LOC119863924,mKIAA0390,RGD1563363,Zfp536,ZNF536
    Uniprot AccessionO15090
    Uniprot Entry NameZN536_HUMAN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000198597
    Target ClassificationN/A

    The target: ZNF536, gene name: ZNF536, also named as . The protein encoded by this gene is a highly conserved zinc finger protein. The encoded protein is most abundant in brain, where it negatively regulates neuronal differentiation. [provided by RefSeq, Sep 2015].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.